Starts in 1 month from now
LocationAthens, Greece.
The Disaster Resilience Days is a multi-day event organised under the Community for European Research and Innovation for Security (CERIS), bringing together experts, policymakers, first responders, and innovators from across Europe and beyond. The event focuses on advancing disaster resilience and preparedness through EU-funded research, technological innovation, and international cooperation.
It features keynote presentations from the European Commission and Member States, panel discussions, live demonstrations of cutting-edge projects, and a walking exhibition, offering opportunities for cross-sector collaboration and knowledge exchange. Key themes include innovation in crisis response, community engagement, secure communication, space technologies, and global partnerships.
As part of the effort to move closer to national communities and deepen local engagement, the next edition of the Disaster Resilience Days will take place in Athens from 6-8 October 2025.
For more information and to register for this event, please access the dedicated page via this link.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.